Home / Compare / Tirzepatide vs Semaglutide
Tirzepatide vs Semaglutide
Tirzepatide vs Semaglutide: how they work, doses used, FDA status and trial weight loss (20.9% vs 14.9%), with sources.
| Tirzepatide | Semaglutide | |
|---|---|---|
| Works on | GIP + GLP-1 (dual agonist) | GLP-1 only |
| How it is taken | Injection, once weekly (Mounjaro, Zepbound) | Injection weekly (Ozempic, Wegovy) or daily tablet |
| US status | FDA-approved (2022 diabetes, 2023 weight) | FDA-approved (2017 diabetes, 2021 weight) |
| Highest dose | 15 mg weekly (label) | 2.4 mg weekly, or 7.2 mg (Wegovy HD, 2026) |
| Key trial | SURMOUNT-1 (phase 3) | STEP 1 (phase 3) |
| Average weight loss | 20.9% at 72 weeks (15 mg weekly) | 14.9% at 68 weeks (2.4 mg weekly) |
| Placebo in that trial | 3.1% | 2.4% |
Head-to-head result
SURMOUNT-5 tested them directly: at 72 weeks, tirzepatide (up to 15 mg) gave 20.2% average weight loss vs 13.7% for semaglutide (up to 2.4 mg).
How they differ
Tirzepatide works on gip + glp-1 (dual agonist); Semaglutide works on glp-1 only. Tirzepatide is taken as: injection, once weekly (mounjaro, zepbound).Semaglutide is taken as: injection weekly (ozempic, wegovy) or daily tablet.
Dose schedules and warnings: Tirzepatide dosage chart ยท Semaglutide dosage chart.
Questions
- Is tirzepatide stronger than semaglutide?
- SURMOUNT-5 tested them directly: at 72 weeks, tirzepatide (up to 15 mg) gave 20.2% average weight loss vs 13.7% for semaglutide (up to 2.4 mg).
- Is tirzepatide FDA-approved?
- FDA-approved (2022 diabetes, 2023 weight).
- Is semaglutide FDA-approved?
- FDA-approved (2017 diabetes, 2021 weight).
Sources
- Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022
- Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021
- Aronne et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM 2025
Last checked 2026-11-16. How we pick and check sources: methodology.